ERF has been identified as a prostate cancer tumor-suppressor gene in a study of localized primary prostate tumors from 102 African-Americans [29] in which recurrent loss-of-function somatic mutations in ERF were observed in 5% of cases. Here, ERF is linked to neoplasm.